CKD-330 Phase 3 Trial in Amlodipine Non-responder

Exclusion Criteria

• •The difference between arms of sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg at Visit 1
• •mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 1
• •mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 2
• •Known or suspected Secondary Hypertension
• •Type I Diabetes Mellitus and Type II Diabetes Mellitus with HbA1c \> 9%
• •Patients with severe congestive heart failure(NYHA class III, IV)
• •Patient with ischemic heart disease, Ischemic cardiovascular disease, Valvular heart disease, arrhythmia requiring treatment within 3 months
• •History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
• •History of severe or malignant retinopathy
• •AST/ALT ≥ UNL\*3, Serum creatinine ≥ UNL\*1.5, K \> 5.5mEq/L
• •Patients with acute or chronic inflammatory status requiring treatment
• •Patient who need to take antihypertensive drug besides Investigational products
• •Patient must be treated with medications prohibited for concomitant use during the study period
• •History of angioedema related to ACE inhibitor or angiotensin II receptor blockers
• •History of disability to drug ADME, active inflammatory bowel syndrome within 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract
• •History of malignant tumor within 5 years
• •Patient who are dependent on drugs or alcohol within 6 months
• •Hypersensitive to Candesartan/Amlodipine
• •Women with pregnant, breast-feeding
• •Patients treated with other investigational product within 30 days at first time taking the investigational product